Literature DB >> 18256417

Effect of Saccharomyces boulardii in the treatment of acute watery diarrhea in Myanmar children: a randomized controlled study.

Khin Htwe1, Khin Saw Yee, Marlar Tin, Yvan Vandenplas.   

Abstract

This study was conducted to evaluate the efficacy of Saccharomyces boulardii in acute diarrhea. One hundred hospitalized children in Myanmar (age range = 3 months to 10 years) were included. Fifty were treated with S. boulardii for five days in addition to oral rehydration solution (ORS) and 50 were given ORS alone (control group) in an alternating order. The mean duration of diarrhea was 3.08 days in the S. boulardii group and 4.68 days (P < 0.05) in the control group. Stools had a normal consistency on day 3 in 38 (76%) of 50 patients in the S. boulardii group compared with only 12 (24%) of 50 in the control group (P = 0.019). On day 2, 27 (54%) of 50 had less than three stools per day in the S. boulardii group compared with only 15 (30%) of 50 in the control group (P = 0.019). Saccharomyces boulardii shortens the duration of diarrhea and normalizes stool consistency and frequency. The shortening of the duration of diarrhea results in a social and economic benefits.

Entities:  

Mesh:

Year:  2008        PMID: 18256417

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  21 in total

1.  Clinical efficacy of Saccharomyces boulardii or metronidazole in symptomatic children with Blastocystis hominis infection.

Authors:  Ener Cagri Dinleyici; Makbule Eren; Nihal Dogan; Serap Reyhanioglu; Zeynel Abidin Yargic; Yvan Vandenplas
Journal:  Parasitol Res       Date:  2010-10-05       Impact factor: 2.289

2.  The effect of a multi-strain probiotic on the resistance toward Escherichia coli challenge in a randomized, placebo-controlled, double-blind intervention study.

Authors:  S J M Ten Bruggencate; S A Girard; E G M Floris-Vollenbroek; R Bhardwaj; T A Tompkins
Journal:  Eur J Clin Nutr       Date:  2014-11-05       Impact factor: 4.016

Review 3.  Probiotics, enteric and diarrheal diseases, and global health.

Authors:  Geoffrey A Preidis; Colin Hill; Richard L Guerrant; B S Ramakrishna; Gerald W Tannock; James Versalovic
Journal:  Gastroenterology       Date:  2010-11-12       Impact factor: 22.682

4.  Clinical efficacy comparison of Saccharomyces boulardii and yogurt fluid in acute non-bloody diarrhea in children: a randomized, controlled, open label study.

Authors:  Makbule Eren; Ener C Dinleyici; Yvan Vandenplas
Journal:  Am J Trop Med Hyg       Date:  2010-03       Impact factor: 2.345

5.  The Effect of a Yeast Probiotic on Acute Diarrhea in Children.

Authors:  Mohammad Reza Sharif; Hamed Haddad Kashani; Abbas Taghavi Ardakani; Davood Kheirkhah; Fatemeh Tabatabaei; Alireza Sharif
Journal:  Probiotics Antimicrob Proteins       Date:  2016-12       Impact factor: 4.609

6.  The Role of Probiotics in the Treatment of Dysentery: a Randomized Double-Blind Clinical Trial.

Authors:  Alireza Sharif; Hamed Haddad Kashani; Elahe Nasri; Zahra Soleimani; Mohammad Reza Sharif
Journal:  Probiotics Antimicrob Proteins       Date:  2017-12       Impact factor: 4.609

7.  Efficacy and safety of Saccharomyces boulardii in acute childhood diarrhea: a double blind randomised controlled trial.

Authors:  Musheer Riaz; Seema Alam; Abida Malik; S Manazir Ali
Journal:  Indian J Pediatr       Date:  2011-10-14       Impact factor: 1.967

Review 8.  Probiotics for treating acute infectious diarrhoea.

Authors:  Stephen J Allen; Elizabeth G Martinez; Germana V Gregorio; Leonila F Dans
Journal:  Cochrane Database Syst Rev       Date:  2010-11-10

Review 9.  Saccharomyces boulardii in childhood.

Authors:  Yvan Vandenplas; Oscar Brunser; Hania Szajewska
Journal:  Eur J Pediatr       Date:  2008-12-19       Impact factor: 3.183

10.  AGA Technical Review on the Role of Probiotics in the Management of Gastrointestinal Disorders.

Authors:  Geoffrey A Preidis; Adam V Weizman; Purna C Kashyap; Rebecca L Morgan
Journal:  Gastroenterology       Date:  2020-06-09       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.